Zai Lab’s zocilurtatug pelitecan secures EMA orphan drug status

Zai Lab has received ODD from the EMA for zocilurtatug pelitecan (zoci), its investigational DLL3-targeting ADC for treating pulmonary NECs. The COMP noted early clinical data indicate Zoci may demonstrate a more favourable effect than existing authorised therapies. Zai Lab plans three registration-enabling studies for Zoci, aiming for completion by the end of 2026. Credit: Gorodenkoff / Shutterstock.com. Zai Lab has received orphan drug designation (ODD) from the European Medicines Agency (EMA) for zocilurtatug pelitecan (Zoci), its investigational delta-like ligand 3 (DLL3)-targeting antibody-drug conjugate (ADC) to treat pulmonary neuroendocrine carcinomas (NECs). The EMA’s Committee for Orphan Medicinal Products (COMP) recommended…

Source: Pharmaceutical Technology